In vivo expansion of activated foxp3+ regulatory t cells and establishment of a type 2 immune response upon il-33 treatment protect against experimental arthritis

Journal of Immunology

Volumn 197, Issue 5, 2016, Pages 1708-1719

  Biton, Jérôme ^a   Athari, Sara Khaleghparast ^a   Thiolat, Allan ^a   Santinon, François ^a   Lemeiter, Delphine ^a   Hervé, Roxane ^a   Delavallée, Laure ^a   Levescot, Anais ^b   Roga, Stéphane ^c   Decker, Patrice ^a   Girard, Jean Philippe ^c   Herbelin, Andre ^d   Boissier, Marie Christophe ^a   Bessis, Natacha ^a  

^a UNIVERSITÉ PARIS 13   (France)

^b POITIERS UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ PAUL SABATIER   (France)

^d AVICENNE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; GAMMA INTERFERON; INTERLEUKIN 33; PROTEIN ST2L; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; APYRASE; CD39 ANTIGEN; COLLAGEN; CYTOKINE; LEUKOCYTE ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; EOSINOPHIL; EXPERIMENTAL ARTHRITIS; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; INNATE IMMUNITY; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION; TH2 CELL; ANIMAL; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASE; BLOOD; CHEMICALLY INDUCED; CYTOLOGY; DBA MOUSE; DISEASE MODEL; DRUG EFFECTS; GENETICS; IMMUNOLOGY; SPLEEN;

ANIMALS; ANTIGENS, CD; APYRASE; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; COLLAGEN; CYTOKINES; DISEASE MODELS, ANIMAL; EOSINOPHILS; INTERLEUKIN-33; MICE; MICE, INBRED DBA; SPLEEN; T-LYMPHOCYTES, REGULATORY; TH2 CELLS;

EID: 84983778420     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1502124     Document Type: Article

References (65)

1. Pecaric-Petkovic, T., S. A. Didichenko, S. Kaempfer, N. Spiegl, and C. A. Dahinden. 2009. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood 113: 1526-1534.
2. Schmitz, J., A. Owyang, E. Oldham, Y. Song, E. Murphy, T. K. McClanahan, G. Zurawski, M. Moshrefi, J. Qin, X. Li, et al. 2005. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23: 479-490.
3. Bourgeois, E., L. P. Van, M. Samson, S. Diem, A. Barra, S. Roga, J. M. Gombert, E. Schneider, M. Dy, P. Gourdy, et al. 2009. The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-γamma production. Eur. J. Immunol. 39: 1046-1055.
4. Besnard, A.-G., D. Togbe, I. Couillin, Z. Tan, S.-G. Zheng, F. Erard, M. Le Bert, V. Quesniaux, and B. Ryffel. 2012. Inflammasome-IL-1-Th17 response in allergic lung inflammation. J. Mol. Cell Biol.4:3-10
5. Licona-Limón, P., L. K. Kim, N. W. Palm, and R. A. Flavell. 2013. TH2, allergy and group 2 innate lymphoid cells. Nat. Immunol. 14: 536-542.
6. Milovanovic, M., V. Volarevic, G. Radosavljevic, I. Jovanovic, N. Pejnovic, N. Arsenijevic, and M. L. Lukic. 2012. IL-33/ST2 axis in inflammation and immunopathology. Immunol. Res. 52: 89-99.
7. Grob, P., K. Doser, W. Falk, F. Obermeier, and C. Hofmann. 2012. IL-33 attenuates development and perpetuation of chronic intestinal inflammation. Inflamm. Bowel Dis. 18: 1900-1909.
8. Jiang, H.-R., M. Milovanović, D. Allan, W. Niedbala, A.-G. Besnard, S. Y. Fukada, J. C. Alves-Filho, D. Togbe, C. S. Goodyear, C. Linington, et al. 2012. IL-33 attenuates EAE by suppressing IL-17 and IFN-γ production and inducing alternatively activated macrophages. Eur. J. Immunol. 42: 1804-1814.
9. Chen, H., Y. Sun, L. Lai, H. Wu, Y. Xiao, B. Ming, M. Gao, H. Zou, P. Xiong, Y. Xu, et al. 2015. Interleukin-33 is released in spinal cord and suppresses experimental autoimmune encephalomyelitis in mice. Neuroscience 308: 157-168.
10. Barbour, M., D. Allan, H. Xu, C. Pei, M. Chen, W. Niedbala, S. Y. Fukada, A.-G. Besnard, J. C. Alves-Filho, X. Tong, et al. 2014. IL-33 attenuates the development of experimental autoimmune uveitis. Eur. J. Immunol. 44: 3320-3329.
11. Miller, A. M., D. Xu, D. L. Asquith, L. Denby, Y. Li, N. Sattar, A. H. Baker, I. B. McInnes, and F. Y. Liew. 2008. IL-33 reduces the development of atherosclerosis. J. Exp. Med. 205: 339-346.
12. Wills-Karp, M., R. Rani, K. Dienger, I. Lewkowich, J. G. Fox, C. Perkins, L. Lewis, F. D. Finkelman, D. E. Smith, P. J. Bryce, et al. 2012. Trefoil factor 2 rapidly induces interleukin 33 to promote type 2 immunity during allergic asthma and hookworm infection. J. Exp. Med. 209: 607-622.
13. Turnquist, H. R., Z. Zhao, B. R. Rosborough, Q. Liu, A. Castellaneta, K. Isse, Z. Wang, M. Lang, D. B. Stolz, X. X. Zheng, et al. 2011. IL-33 expands suppressive CD11b+ Gr-1(int) and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival. J. Immunol. 187: 4598-4610.
14. Gajardo, T., R. A. Morales, M. Campos-Mora, J. Campos-Acuña, and K. Pino-Lagos. 2015. Exogenous interleukin-33 targets myeloid-derived suppressor cells and generates periphery-induced Foxp3? regulatory T cells in skin-transplanted mice. Immunology 146: 81-88.
15. Boissier, M.-C. 2011. Cell and cytokine imbalances in rheumatoid synovitis. Joint Bone Spine 78: 230-234.
16. Nadkarni, S., C. Mauri, and M. R. Ehrenstein. 2007. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-βeta. J. Exp. Med. 204: 33-39.
17. Morgan, M. E., R. P. Sutmuller, H. J. Witteveen, L. M. van Duivenvoorde, E. Zanelli, C. J. Melief, A. Snijders, R. Offringa, R. R. de Vries, and R. E. Toes. 2003. CD25+ cell depletion hastens the onset of severe disease in collageninduced arthritis. Arthritis Rheum. 48: 1452-1460.
18. Nguyen, L. T., J. Jacobs, D. Mathis, and C. Benoist. 2007. Where FoxP3-dependent regulatory T cells impinge on the development of inflammatory arthritis. Arthritis Rheum. 56: 509-520.
19. Carriere, V., L. Roussel, N. Ortega, D. A. Lacorre, L. Americh, L. Aguilar, G. Bouche, and J. P. Girard. 2007. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc. Natl. Acad. Sci. USA 104: 282-287.
20. Talabot-Ayer, D., C. Gabay, and G. Palmer. 2013. Reply to Xie et al. about the article Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Joint Bone Spine 80: 117-118.
21. Kashiwakura, J., M. Yanagisawa, H. Lee, Y. Okamura, T. Sasaki-Sakamoto, S. Saito, Y. Tokuhashi, C. Ra, and Y. Okayama. 2013. Interleukin-33 synergistically enhances immune complex-induced tumor necrosis factor alpha and interleukin-8 production in cultured human synovium-derived mast cells. Int. Arch. Allergy Immunol. 161(Suppl. 2): 32-36.
22. Leung, B. P., D. Xu, S. Culshaw, I. B. McInnes, and F. Y. Liew. 2004. A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J. Immunol. 173: 145-150.
23. Palmer, G., D. Talabot-Ayer, C. Lamacchia, D. Toy, C. A. Seemayer, S. Viatte, A. Finckh, D. E. Smith, and C. Gabay. 2009. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum. 60: 738-749.
24. Xu, D., H. R. Jiang, P. Kewin, Y. Li, R. Mu, A. R. Fraser, N. Pitman, M. Kurowska-Stolarska, A. N. McKenzie, I. B. McInnes, and F. Y. Liew. 2008. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc. Natl. Acad. Sci. USA 105: 10913-10918.
25. Martin, P., D. Talabot-Ayer, C. A. Seemayer, S. Vigne, C. Lamacchia, E. Rodriguez, A. Finckh, D. E. Smith, C. Gabay, and G. Palmer. 2013. Disease severity in K/BxN serum transfer-induced arthritis is not affected by IL-33 deficiency. Arthritis Res. Ther. 15: R13.
26. Talabot-Ayer, D., P. Martin, C. A. Seemayer, S. Vigne, C. Lamacchia, A. Finckh, E. Saiji, C. Gabay, and G. Palmer. 2014. Immune-mediated experimental arthritis in IL-33 deficient mice. Cytokine 69: 68-74.
27. Clavel, G., C. Valvason, K. Yamaoka, D. Lemeiter, L. Laroche, M. C. Boissier, and N. Bessis. 2006. Relationship between angiogenesis and inflammation in experimental arthritis. Eur. Cytokine Netw. 17: 202-210.
28. Saidenberg-Kermanac'h, N., N. Bessis, D. Lemeiter, M. C. de Vernejoul, M. C. Boissier, and M. Cohen-Solal. 2004. Interleukin-4 cellular gene therapy and osteoprotegerin decrease inflammation-associated bone resorption in collagen-induced arthritis. J. Clin. Immunol. 24: 370-378.
29. Wen, T., J. A. Besse, M. K. Mingler, P. C. Fulkerson, and M. E. Rothenberg. 2013. Eosinophil adoptive transfer system to directly evaluate pulmonary eosinophil trafficking in vivo. Proc. Natl. Acad. Sci. USA 110: 6067-6072.
30. Löhning, M., A. Stroehmann, A. J. Coyle, J. L. Grogan, S. Lin, J. C. Gutierrez-Ramos, D. Levinson, A. Radbruch, and T. Kamradt. 1998. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc. Natl. Acad. Sci. USA 95: 6930-6935.
31. Klein Wolterink, R. G. J., A. Kleinjan, M. van Nimwegen, I. Bergen, M. de Bruijn, Y. Levani, and R. W. Hendriks. 2012. Pulmonary innate lymphoid cells are major producers of IL-5 and IL-13 in murine models of allergic asthma. Eur. J. Immunol. 42: 1106-1116.
32. Brickshawana, A., V. S. Shapiro, H. Kita, and L. R. Pease. 2011. Lineage2Sca1+ c-Kit2CD25+ cells are IL-33-responsive type 2 innate cells in the mouse bone marrow. J. Immunol. 187: 5795-5804.
33. Fletcher, J. M., R. Lonergan, L. Costelloe, K. Kinsella, B. Moran, C. O'Farrelly, N. Tubridy, and K. H. Mills. 2009. CD39+Foxp3+ regulatory T cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J. Immunol. 183: 7602-7610.
34. Ye, Z. J., Q. Zhou, J. C. Zhang, X. Li, C. Wu, S. M. Qin, J. B. Xin, and H. Z. Shi. 2011. CD39+ regulatory T cells suppress generation and differentiation of Th17 cells in human malignant pleural effusion via a LAP-dependent mechanism. Respir. Res. 12: 77.
35. Sauer, A. V., I. Brigida, N. Carriglio, R. J. Hernandez, S. Scaramuzza, D. Clavenna, F. Sanvito, P. L. Poliani, N. Gagliani, F. Carlucci, et al. 2012. Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID. Blood 119: 1428-1439.
36. Bessis, N., M. C. Boissier, P. Ferrara, T. Blankenstein, D. Fradelizi, and C. Fournier. 1996. Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete interleukin-13. Eur. J. Immunol. 26: 2399-2403.
37. Cottard, V., D. Mulleman, P. Bouille, M. Mezzina, M. C. Boissier, and N. Bessis. 2000. Adeno-associated virus-mediated delivery of IL-4 prevents collageninduced arthritis. Gene Ther. 7: 1930-1939.
38. Reynolds, J. M., P. Angkasekwinai, and C. Dong. 2010. IL-17 family member cytokines: regulation and function in innate immunity. Cytokine Growth Factor Rev. 21: 413-423.
39. Cua, D. J., and C. M. Tato. 2010. Innate IL-17-producing cells: the sentinels of the immune system. Nat. Rev. Immunol. 10: 479-489.
40. Moran, E. M., R. Heydrich, C. T. Ng, T. P. Saber, J. McCormick, J. Sieper, H. Appel, U. Fearon, and D. J. Veale. 2011. IL-17A expression is localised to both mononuclear and polymorphonuclear synovial cell infiltrates. PLoS One 6: e24048.
41. Bonilla, W. V., A. Fröhlich, K. Senn, S. Kallert, M. Fernandez, S. Johnson, M. Kreutzfeldt, A. N. Hegazy, C. Schrick, P. G. Fallon, et al. 2012. The alarmin interleukin-33 drives protective antiviral CD8? T cell responses. Science 335: 984-989.
42. Chen, J., L. Duan, A. Xiong, H. Zhang, F. Zheng, Z. Tan, F. Gong, and M. Fang. 2012. Blockade of IL-33 ameliorates Con A-induced hepatic injury by reducing NKT cell activation and IFN-γ production in mice. J. Mol. Med. 90: 1505-1515.
43. Walker, J. A., J. L. Barlow, and A. N. McKenzie. 2013. Innate lymphoid cells-how did we miss them? Nat. Rev. Immunol. 13: 75-87.
44. Nie, H., Y. Zheng, R. Li, T. B. Guo, D. He, L. Fang, X. Liu, L. Xiao, X. Chen, B. Wan, et al. 2013. Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-a in rheumatoid arthritis. Nat. Med. 19: 322-328.
45. Biton, J., L. Semerano, L. Delavallée, D. Lemeiter, M. Laborie, G. Grouard-Vogel, M. C. Boissier, and N. Bessis. 2011. Interplay between TNF and regulatory T cells in a TNF-driven murine model of arthritis. J. Immunol. 186: 3899-3910.
46. Volarevic, V., M. Mitrovic, M. Milovanovic, I. Zelen, I. Nikolic, S. Mitrovic, N. Pejnovic, N. Arsenijevic, and M. L. Lukic. 2012. Protective role of IL-33/ST2 axis in Con A-induced hepatitis. J. Hepatol. 56: 26-33.
47. Schiering, C., T. Krausgruber, A. Chomka, A. Fröhlich, K. Adelmann, E. A.Wohlfert, J. Pott, T. Griseri, J. Bollrath, A. N. Hegazy, et al. 2014. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature 513: 564-568.
48. Duan, L., J. Chen, H. Zhang, H. Yang, P. Zhu, A. Xiong, Q. Xia, F. Zheng, Z. Tan, F. Gong, and M. Fang. 2012. Interleukin-33 ameliorates experimental colitis through promoting Th2/Foxp3? regulatory T-cell responses in mice. Mol. Med. 18: 753-761.
49. Matta, B. M., J. M. Lott, L. R. Mathews, Q. Liu, B. R. Rosborough, B. R. Blazar, and H. R. Turnquist. 1950. 2014. IL-33 is an unconventional alarmin that stimulates IL-2 secretion by dendritic cells to selectively expand IL-33R/ST2+ regulatory T cells. J. Immunol. 193: 4010-4020.
50. Morita, H., K. Arae, H. Unno, K. Miyauchi, S. Toyama, A. Nambu, K. Oboki, T. Ohno, K. Motomura, A. Matsuda, et al. 2015. An interleukin-33-mast cellinterleukin-2 axis suppresses papain-induced allergic inflammation by promoting regulatory T cell numbers. Immunity 43: 175-186.
51. Thiolat, A., L. Semerano, Y. M. Pers, J. Biton, D. Lemeiter, P. Portales, J. Quentin, C. Jorgensen, P. Decker, M.-C. Boissier, et al. 2014. Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritis. Arthritis Rheumatol. 66: 273-283.
52. Ehrenstein, M. R., J. G. Evans, A. Singh, S. Moore, G. Warnes, D. A. Isenberg, and C. Mauri. 2004. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J. Exp. Med. 200: 277-285.
53. Kamradt, T., and S. Drube. 2013. A complicated liaison: IL-33 and IL-33R in arthritis pathogenesis. Arthritis Res. Ther. 15: 115.
54. Anthony, R. M., T. Kobayashi, F. Wermeling, and J. V. Ravetch. 2011. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 475: 110-113.
55. Zaiss, M. M., M. Kurowska-Stolarska, C. Böhm, R. Gary, C. Scholtysek, B. Stolarski, J. Reilly, S. Kerr, N. L. Millar, T. Kamradt, et al. 2011. IL-33 shifts the balance from osteoclast to alternatively activated macrophage differentiation and protects from TNF-alpha-mediated bone loss. J. Immunol. 186: 6097-6105.
56. Boissier, M. C., G. Chiocchia, N. Bessis, J. Hajnal, G. Garotta, F. Nicoletti, and C. Fournier. 1995. Biphasic effect of interferon-gamma in murine collageninduced arthritis. Eur. J. Immunol. 25: 1184-1190.
57. Nakajima, H., H. Takamori, Y. Hiyama, and W. Tsukada. 1990. The effect of treatment with interferon-gamma on type II collagen-induced arthritis. Clin. Exp. Immunol. 81: 441-445.
58. Williams, R. O., D. G.Williams, M. Feldmann, and R. N. Maini. 1993. Increased limb involvement in murine collagen-induced arthritis following treatment with anti-interferon-gamma. Clin. Exp. Immunol. 92: 323-327.
59. Manoury-Schwartz, B., G. Chiocchia, N. Bessis, O. Abehsira-Amar, F. Batteux, S. Muller, S. Huang, M. C. Boissier, and C. Fournier. 1997. High susceptibility to collagen-induced arthritis in mice lacking IFN-γamma receptors. J. Immunol. 158: 5501-5506.
60. Vermeire, K., H. Heremans, M. Vandeputte, S. Huang, A. Billiau, and P. Matthys. 1997. Accelerated collagen-induced arthritis in IFN-γamma receptor-deficient mice. J. Immunol. 158: 5507-5513.
61. Schurgers, E., A. Billiau, and P. Matthys. 2011. Collagen-induced arthritis as an animal model for rheumatoid arthritis: focus on interferon-g. J. Interferon Cytokine Res. 31: 917-926.
62. Zheng, Z., T. Liu, X. Li, J. Ding, Y. Feng, J. Miao, X. Luo, Z. Wu, and P. Zhu. 2015. Kinetic changes of regulatory B10 cells in collagen-induced arthritis could be regulated by cytokines IFN-γ and TGF-β1. Inflamm. Res. 64: 637-645.
63. Kelchtermans, H., E. Schurgers, L. Geboes, T. Mitera, J. Van Damme, J. Van Snick, C. Uyttenhove, and P. Matthys. 2009. Effector mechanisms of interleukin-17 in collagen-induced arthritis in the absence of interferon-gamma and counteraction by interferon-gamma. Arthritis Res. Ther. 11: R122.
64. Olalekan, S. A., Y. Cao, K. M. Hamel, and A. Finnegan. 2015. B cells expressing IFN-γ suppress Treg-cell differentiation and promote autoimmune experimental arthritis. Eur. J. Immunol. 45: 988-998.
65. Finnegan, A., K. Mikecz, P. Tao, and T. T. Glant. 1999. Proteoglycan (aggrecan)-induced arthritis in BALB/c mice is a Th1-type disease regulated by Th2 cytokines. J. Immunol. 163: 5383-5390.